CN107753500A - The Preparation method and use of oligosaccharide compositions in the wind-weed - Google Patents
The Preparation method and use of oligosaccharide compositions in the wind-weed Download PDFInfo
- Publication number
- CN107753500A CN107753500A CN201711072456.9A CN201711072456A CN107753500A CN 107753500 A CN107753500 A CN 107753500A CN 201711072456 A CN201711072456 A CN 201711072456A CN 107753500 A CN107753500 A CN 107753500A
- Authority
- CN
- China
- Prior art keywords
- weed
- wind
- water
- constipation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 51
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 206010010774 Constipation Diseases 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 230000002475 laxative effect Effects 0.000 claims abstract description 10
- 239000011347 resin Substances 0.000 claims abstract description 9
- 229920005989 resin Polymers 0.000 claims abstract description 9
- 230000002650 habitual effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 238000005057 refrigeration Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 abstract description 7
- 235000005911 diet Nutrition 0.000 abstract description 4
- 230000037213 diet Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 18
- 239000000976 ink Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 230000000968 intestinal effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000001809 melena Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000013872 defecation Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- -1 compound diphenoxylate Chemical class 0.000 description 4
- 229960004192 diphenoxylate Drugs 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 239000006101 laboratory sample Substances 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960005132 cisapride Drugs 0.000 description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to the preparation method and applications of the oligosaccharide compositions in the wind-weed with laxative action.The present invention is from rhizoma ane marrhenae（Rhizoma anemarrhenae）The macroreticular resin water elution components of D 101 are prepared.Proved through experimental study, the component has obvious laxative action, is used available for treatment elderly constipation, habitual constipation and as diet products.
Description
Technical field：
The present invention relates to the wind-weed（Rhizoma anemarrhenae）The preparation method and its medical usage of middle oligosaccharide compositions, especially
Be prepare treatment habitual constipation, atonic constipation, constipation in children medicine purposes.
Background technology：
Constipation is clinical common complicated symptom, with the change of people's dietary structure and psychiatric and the shadow of social factor
Ring, the constipation incidence of disease, which has, increases trend, annoyings many people, has a strong impact on their quality of life.Easily there are intestines in constipation crowd
Road Flora Disturbance, prolonged constipation also have close relationship with acute cardiovascular and cerebrovascular disease, dementia, colorectal cancer etc..Stool excretion
It is the main path that vivotoxin and waste product exclude, if stool is deposited in enteron aisle, can constantly produces various poison gases, toxin,
Cause enteral environmental degradation, functions of intestines and stomach disorder, endocrinopathy, metabolic disturbance, the poor, stress of diet sleep etc..
Stool oppresses intestinal wall, makes intestinal mucosa injured, and enterocinesia is slack-off, fat deposition in intestinal wall, is unfavorable for the conversion of fat, for a long time so
Habitual constipation and obesity may be caused.Constipation can be alleviated initially through changing lifestyles, but the time is longer, needs medicine to do
Relate to, need to consider surgical radical treatment if invalid, removing stool can make patient break away from above-mentioned puzzlement.Western medicine is bright to solving anti-constipation effect
It is aobvious, but have adverse reaction and side effect and a high recurrence rate, Western medicine more focuses on that As the medicine took effect, the symptoms lessened, cures the symptoms, not the disease, easily bounce-back is multiple
Hair, long-term use can produce generation drug resistance, often to increase dose or can just be taken effect using different types of medicine.Chinese medicine is controlled
The recovery that entirety is then more focused in constipation is treated, the interior environment by improving human body improves the ability of human body resist the disease, treats both principal and secondary aspect of disease,
Small side effects, there is obvious advantage with Western medicine control.
The wind-weed is the Liliaceae wind-weed platymiscium wind-weed（Anemarrhena asphodeloidesBge.）Dry root shape
Stem.Its energy clearing heat-fire, nourishing Yin and moistening dryness.It is bitter, sweet, it is cold in nature, enter lung, stomach, kidney channel, record in 2015 editions《Chinese Pharmacopoeia》.Also
There is Traditional Chinese Medicine to think the wind-weed " hardship can rush down kidney fire and sharp neatly intestines ".The present inventor has found the widow with laxative action from the wind-weed
Saccharic composition, and the preparation method of the component is determined.Inside and outside pharmacodynamic experiment shows that there is this component preferable laxative to make
With being used available for treatment elderly constipation, habitual constipation and as diet products.
Research report at present for wind-weed carbohydrate content is less, and the present invention is carried out using Phytochemistry as means to the wind-weed
Extracting and developing, purifying, first from rhizoma ane marrhenae isolated treatment constipation active component, pass through In vitroandin vivotrial
Its drug effect is evaluated, and is prepared into the medicine for the treatment of constipation.
The content of the invention：
The therapeutic scheme of the present invention is to be based on traditional Chinese medical theory, the principle of reatment determined for the pathogenetic understanding of constipation,
And by substantial amounts of experimental study, from a kind of wind-weed（Rhizoma anemarrhenae）In, by reasonably extracting, refining,
Obtain a kind of oligosaccharide compositions for being used to treat constipation.The pharmacological action of the oligosaccharide compositions is preferable, has no toxic side effect.The present invention simultaneously
Additionally provide the preparation method of clinical applicable formulation.
The present invention is realized in following method：
Oligosaccharide compositions of the present invention, it is after rhizoma ane marrhenae adds water to cook, the water-soluble component obtained is separated through macroreticular resin.
The water-soluble component has laxative action, is the drug therapy of constipation patient for preparing the medicine or food for the treatment of constipation
Provide new selection.
The preparation method of the pharmaceutical dosage form of clinical practice of the present invention, it is characterised in that：
（1）After the water that rhizoma ane marrhenae plus 5 times are measured is soaked 30 minutes, heating decocts 3 times, 2 hours every time, obtains aqueous extract,
Filtering merges extract solution, is recovered under reduced pressure, obtained clear cream is dissolved in after water and is slowly added into 95% ethanol, make its final concentration of alcohol
Up to 70%, it is sufficiently stirred, refrigeration 12 hours, leaching supernatant in refrigerator, is recovered under reduced pressure to without alcohol taste, obtains rhizoma ane marrhenae extraction
Liquid.
（2）By step（1）Rhizoma ane marrhenae extract solution is added on processed good macroporous absorbent resin, using water as eluent,
10 times of column volumes are eluted, eluent is collected respectively, eluent is concentrated under reduced pressure, are dried, i.e. oligosaccharide compositions.
（3）By the oligosaccharide compositions of preparation, according to the formulation method of pharmacy, right amount of auxiliary materials is added, different formulations is made.
The present invention is relative to the advantage of prior art：
It is used clinically for the treatment and prevention of habitual constipation, atonic constipation, constipation in children.
Utilize the pharmacology of pharmaceutical preparation produced by the invention, pharmacodynamic study, it was demonstrated that it has laxative action, for treating
Constipation.
The preparation method of oligosaccharide compositions with laxative action in the wind-weed of the present invention, simple process is easily operated,
Reappearance is good, and cost is low, is easy to mass produce.
Embodiment
In order to inquire into the effective substance of the oligosaccharides based composition of wind-weed treatment constipation, active component, the present invention are found
The inside and outside pharmacodynamic experiment of body is carried out using the Pharmacological Test Method of correlation, evaluates isolated oligosaccharide kind group from the wind-weed
The drug effect of compound, illustrate medicinal usage of the oligosaccharides based composition of the wind-weed in terms of for treating constipation.
The present invention will further be described in detail below.It is pointed out that following explanation is only to application claims
Protection technical scheme is for example, not to any restrictions of these technical schemes.Protection scope of the present invention is with appended
The content that claims are recorded is defined.
1. mouse defecation is tested
1.1 laboratory sample
The preparation of sample and positive control drug solns：Test sample is the oligosaccharide compositions and the positive prepared in embodiment 1
Comparison medicine Maren wan（Nanjing Tongrentang medicine company）.Accurately weigh appropriate amount of sample, be configured to distilled water by doubling dilution needed for
The solution of concentration, i.e. 2 g/kg, 4 g/kg, 8 g/kg, 2.4 g/kg supply laxative pharmacology evaluation of effect.
1.2 experimental method
Kunming mice adaptability is fed one week, is taken healthy mice 48, male and female half and half, is randomly divided into 6 groups, every group 8, experiment is set
Blank group, model group, positive drug group（Maren wan）, oligosaccharide compositions high dose group, oligosaccharide compositions middle dose group, low dose of oligosaccharide compositions
Amount group, daily gavage once, continuous 7 d.The h of water 24, model group, positive drug are can't help in each group mouse fasting after last gives medicine
Group and each experimental group compound diphenoxylate gavage（30 mg/kg bw）, blank group gives distilled water.After 30 min, blank group
Prepared Chinese ink gavage is given with model group, positive drug group and each experimental group give the prepared Chinese ink containing relative medicine, and every mouse is individually put
Put and start timing.Observe and record mouse arrange the melena time first, defecation grain number and weight in 6 h.
1.3 experimental result
Statistics medicine mouse is arranged first the melena time, in 6 h defecation grain number and weight influence, as a result such as table 1.With blank group
Contrast, model group mouse arranges the melena time first, defecation grain number and weight in 6 hP<0.01, it was demonstrated that modeling success.Each experimental group
Compared with model group, using the first grain melena time as index, the height at positive drug group and water elution position, middle dose group have pole
Significant difference（P<0.01）；Using fecal grains in 6 h as index, height, the middle dose group tool at positive drug group and water elution position
There is pole significant difference（P<0.01）, water elution position has significant difference（P<0.05）；Using stool weight in 6 h as finger
The height of mark, positive drug group and oligosaccharide compositions, middle dose group have pole significant difference（P<0.01）, water elution position has notable
Sex differernce（P<0.05）.Illustrate that wind-weed water elution position can significantly alleviate mice with constipation caused by compound diphenoxylate.
Influence of the medicine of table 1 to fecal grains and weight in mice with constipation first grain melena time, 6 h（, n=8）
Note：Compared with model group* P<0.05,** P<0.01, model group is compared with blank group# P<0.05,## P<0.01
2 small intestine push are tested
2.1 laboratory sample
The preparation of sample and positive control drug solns：Test sample is the oligosaccharide compositions and the positive prepared in embodiment 1
Comparison medicine Maren wan（Nanjing Tongrentang medicine company）.Accurately weigh appropriate amount of sample, be configured to distilled water by doubling dilution needed for
The solution of concentration, i.e. 2 g/kg, 4 g/kg, 8 g/kg, 2.4 g/kg supply laxative pharmacology evaluation of effect.
2.2 experimental method
Kunming mice adaptability is fed 1 week, is taken healthy mice 48, male and female half and half, is randomly divided into 6 groups, every group of 8 mouse are real
Test and set blank group, model group, positive drug group（Maren wan）, oligosaccharide compositions high dose group, oligosaccharide compositions middle dose group, oligosaccharide compositions
Low dose group, daily gavage 1 time, continuous 7 d.The h of water 24, model group, the positive are can't help in each group mouse fasting after last gives medicine
Medicine group and each experimental group compound diphenoxylate gavage（30 mg/kg·bw）, blank group gives distilled water.After 30 min, blank
Group and model group give prepared Chinese ink gavage, and positive drug group and each experimental group give the prepared Chinese ink containing relative medicine；After 15 min, take off immediately
Cervical vertebra puts to death mouse, opens abdominal cavity separation mesenterium, clip upper end is from the intestinal tube of pylorus, lower end to ileocecus, gently by small intestine
Straight line is pulled into, small intestinal length is measured and prepared Chinese ink promotes length.Length of intestine is " total small intestinal length ", is from pylorus to prepared Chinese ink forward position
" prepared Chinese ink propulsion length ".Ink progradation is calculated by following equation：
Ink progradation（%）=prepared Chinese ink promotes length/total small intestinal length × 100%
2.3 experimental result
Influence of the medicine to mouse ink progradation is counted, as a result such as table 2.Contrasted with blank group, model group mouse prepared Chinese ink promotes
RateP<0.05, it was demonstrated that modeling success.Compared with model group, positive drug group and oligosaccharide compositions height, middle dose group have each experimental group
Pole significant difference（P<0.01）, the low dose group of oligosaccharide compositions has significant difference（P<0.05）, oligosaccharide compositions can be significantly
Increase mouse ink progradation, show that wind-weed oligosaccharide compositions remarkably promote the enterocinesia of compound diphenoxylate constipation induced mouse.
Influence of the medicine of table 2 to ink progradation（, n=8）
| Dosage group | Dosage（g/kg） | Prepared Chinese ink advance distance（cm） | Small intestine total length（cm） | Ink progradation（%） |
| Blank group | 25.001.70 | 49.502.35 | 50.481.75* | |
| Model group | 3×10-5 | 18.012.69 | 45.483.31 | 39.695.78# |
| Positive drug group | 2.4 | 31.884.64 | 44.133.36 | 72.309.27** |
| Oligosaccharide compositions high dose group | 8 | 30.343.13 | 47.283.57 | 64.306.32** |
| Oligosaccharide compositions middle dose group | 4 | 26.304.47 | 43.354.65 | 60.748.43** |
| Oligosaccharide compositions low dose group | 2 | 21.783.91 | 45.234.20 | 48.227.69* |
Note：Compared with model group* P<0.05,** P<0.01, model group is compared with blank group#P<0.05,##P<0.01
3 intestinal smooth muscle exercise testings
3.1 laboratory sample
The preparation of sample and positive control drug solns：Test sample is the oligosaccharide compositions and the positive prepared in embodiment 1
Comparison medicine Cisapride（Shandong Zycon medicine company）.Accurately weigh appropriate amount of sample, be configured to distilled water by doubling dilution needed for
The solution of concentration, i.e. 1 mg/mL, 4 mg/mL, 16 mg/mL, the outer intestinal smooth muscle exercise testing evaluation of 0.1 mg/mL donors.
3.2 experimental method
Experiment sets blank group, positive drug group（Cisapride）, oligosaccharide compositions high dose group, oligosaccharide compositions middle dose group, oligosaccharides group
Divide low dose group.Rat Fast can't help the h of water 24 before experiment, and cervical dislocation splits abdominal cavity immediately after putting to death, take out duodenum 2
Cm is put into rapidly in 37 DEG C of krebs solutions.Mucous membrane is removed, cleans intestinal contents.Bath bottom ventilation lateral bending is fixed in one end of intestines
On hook, the other end is connected with transducer, is put into 37 DEG C of krebs solution baths and passes to 95%O2And 5%CO2, the g of tension load about 1,
Stable about 50 min, after system is stable, each 5 min intestines are smooth before and after observing and recording tension curve and giving various dose component
Flesh bar contractive amplitude.
3.3 experimental result
Influence of the medicine to 5 min before and after rat preduodenal intestinal segment is counted, as a result such as table 3.5 min compare 12 before and after administration
Duodenum 12 intestinal segment contractive amplitude, positive drug group, the height of oligosaccharide compositions, middle dose group have pole significant difference（P<0.01）, oligosaccharides
Component low dose group has significant difference（P<0.05）, other components are without significant difference.Show that wind-weed oligosaccharide compositions have to promote
Enter the effect of rat enterocinesia.
Influence of the medicine of table 3 to rat preduodenal contractive amplitude（）
| Group | Dosage mg/mL | 5 min contractive amplitudes before administration | 5 min contractive amplitudes after administration |
| Blank group | 0.840.16 | 0.810.13 | |
| Positive drug group | 0.1 | 0.970.10 | 2.020.06** |
| Oligosaccharide compositions high dose group | 16 | 1.130.17 | 1.810.05** |
| Oligosaccharide compositions middle dose group | 4 | 1.060.06 | 1.500.03** |
| Oligosaccharide compositions low dose group | 1 | 1.040.14 | 1.370.10* |
The present invention is arranged black using the experiment of mouse defecation, small intestine push experiment and external intestinal smooth muscle exercise testing with small mouse's head grain
Just the time, the change of melena number and weight, ink progradation and rat preduodenal contractive amplitude turns to evaluation and referred in 6 h
Mark, it is found that wind-weed water extract D-101 macroreticular resin water elution components can significantly improve mice with constipation situation, and can significantly improve big
Mouse duodenum smooth muscle contraction amplitude.
Embodiment 1
（1）After adding the water of 5 times of amounts to soak 30 minutes the kg of rhizoma ane marrhenae 10, heating decocts 3 times, 2 hours every time, obtains water extraction
Liquid is taken, filtering merges extract solution, is recovered under reduced pressure, obtained clear cream is dissolved in after water and is slowly added into 95% ethanol, make its final ethanol
Concentration is sufficiently stirred, refrigeration 12 hours, leaching supernatant, are recovered under reduced pressure to without alcohol taste, obtain rhizoma ane marrhenae in refrigerator up to 70%
Extract solution.
（2）By step（1）Rhizoma ane marrhenae extract solution is added on processed good D-101 macroporous absorbent resins, using water to wash
De- liquid, elutes 10 times of column volumes, collects eluent, eluent is concentrated under reduced pressure, and dries, i.e. oligosaccharide compositions.
（3）By the oligosaccharide compositions of preparation, according to the formulation method of pharmacy, right amount of auxiliary materials granulation is added, it is total mixed, pour into glue
Capsule, capsule is made.
Embodiment 2
（1）10% alcohol reflux that the kg of rhizoma ane marrhenae 10 adds 6 times of amounts is extracted 3 times, 2 hours every time, aqueous extract is obtained, filters
Merge extract solution, be recovered under reduced pressure, obtained clear cream is dissolved in after water and is slowly added into 95% ethanol, reach its final concentration of alcohol
70%, it is sufficiently stirred, refrigeration 12 hours, leaching supernatant, are recovered under reduced pressure to without alcohol taste, obtain rhizoma ane marrhenae extract solution in refrigerator.
（2）By step（1）Rhizoma ane marrhenae extract solution is added on processed good D-101 macroporous absorbent resins, using water to wash
De- liquid, elutes 10 times of column volumes, collects eluent, eluent is concentrated under reduced pressure, and dries, i.e. oligosaccharide compositions.
（3）By the oligosaccharide compositions of preparation, according to the formulation method of pharmacy, right amount of auxiliary materials granulation is added, total mixed, tabletting,
Coating, is made piece type.
Embodiment 3
（1）After adding the water of 5 times of amounts to soak 30 minutes the kg of rhizoma ane marrhenae 10, heating decocts 3 times, 2 hours every time, obtains water extraction
Liquid is taken, filtering merges extract solution, is recovered under reduced pressure, obtained clear cream is dissolved in after water and is slowly added into 95% ethanol, make its final ethanol
Concentration is sufficiently stirred, refrigeration 12 hours, leaching supernatant, are recovered under reduced pressure to without alcohol taste, obtain rhizoma ane marrhenae in refrigerator up to 70%
Extract solution.
（2）By step（1）Rhizoma ane marrhenae extract solution is added on processed good D-101 macroporous absorbent resins, using water to wash
De- liquid, elutes 10 times of column volumes, collects eluent, eluent is concentrated under reduced pressure, and dries, i.e. oligosaccharide compositions.
（3）By the oligosaccharide compositions of preparation, according to the formulation method of pharmacy, right amount of auxiliary materials is added, is well mixed, it is filling,
Oral liquid is made.
Claims (3)
1. the oligosaccharides based composition of a kind of wind-weed, it is characterised in that the oligosaccharides based composition is warp after rhizoma ane marrhenae adds water to cook
The water-soluble component that macroreticular resin separation obtains, concrete operations follow these steps to carry out：
（1）After the water that rhizoma ane marrhenae plus 5 times are measured is soaked 30 minutes, heating decocts 3 times, 2 hours every time, obtains aqueous extract,
Filtering merges extract solution, is recovered under reduced pressure, obtained clear cream is dissolved in after water and is slowly added into 95% ethanol, make its final concentration of alcohol
Up to 70%, it is sufficiently stirred, refrigeration 12 hours, leaching supernatant in refrigerator, is recovered under reduced pressure to without alcohol taste, obtains rhizoma ane marrhenae extraction
Liquid；
（2）By step（1）Rhizoma ane marrhenae extract solution is added on processed good D-101 macroporous absorbent resins, using water as eluent,
10 times of column volumes are eluted, eluent is collected respectively, eluent is concentrated under reduced pressure, are dried, i.e. the oligosaccharide compositions of the wind-weed.
2. the purposes of the oligosaccharides based composition of the wind-weed as claimed in claim 1, it is characterised in that described oligosaccharides based composition tool
Have laxative action, for prepare treatment habitual constipation, atonic constipation, constipation in children medicine or food.
3. the purposes of the oligosaccharides based composition of the wind-weed as claimed in claim 1, it is characterised in that pharmaceutically acceptable carrier is added,
Prepare piece agent, capsule, granule, oral liquid, pill or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711072456.9A CN107753500A (en) | 2017-11-03 | 2017-11-03 | The Preparation method and use of oligosaccharide compositions in the wind-weed |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711072456.9A CN107753500A (en) | 2017-11-03 | 2017-11-03 | The Preparation method and use of oligosaccharide compositions in the wind-weed |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107753500A true CN107753500A (en) | 2018-03-06 |
Family
ID=61272175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711072456.9A Pending CN107753500A (en) | 2017-11-03 | 2017-11-03 | The Preparation method and use of oligosaccharide compositions in the wind-weed |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107753500A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115572318A (en) * | 2022-10-23 | 2023-01-06 | 爱生泽(上海)生物科技有限公司 | Preparation method of anemarrhena oligosaccharide and application of anemarrhena oligosaccharide in cosmetics |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1594246A (en) * | 2003-09-10 | 2005-03-16 | 苏州市思源医药科技有限公司 | Rhizoma Anemarrhenae total phenol extract, its preparation method and application |
| KR20080045770A (en) * | 2006-11-21 | 2008-05-26 | 김우원 | Process of manufacturing korean bread contining korean medicine |
| CN101229316A (en) * | 2008-01-31 | 2008-07-30 | 广东药学院 | Rhizoma anemarrhenae extrac and applications as type 2 diabetes-curing medicine thereof |
| JP2011157344A (en) * | 2009-10-23 | 2011-08-18 | Kracie Seiyaku Kk | Aroma composition having action for improving psychosomatic disorder and for upgrading action efficiency of brain, and preparation including the same |
| CN103479856A (en) * | 2013-09-22 | 2014-01-01 | 山东省医药工业研究所 | Rhizoma anemarrhenae chemical component cluster extracts and preparation process thereof |
| CN103830520A (en) * | 2012-11-26 | 2014-06-04 | 青岛百草汇中草药研究所 | New application of total saponins of rhizoma anemarrhenae |
| CN105596684A (en) * | 2016-02-01 | 2016-05-25 | 北京宜生堂医药科技研究有限公司 | Rhizoma anemarrhenae extract and lily and rhizoma anemarrhenae extract |
| CN105663626A (en) * | 2016-03-04 | 2016-06-15 | 广东药学院 | Rhizoma anemarrhenae effective part as well as preparation method and application thereof |
-
2017
- 2017-11-03 CN CN201711072456.9A patent/CN107753500A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1594246A (en) * | 2003-09-10 | 2005-03-16 | 苏州市思源医药科技有限公司 | Rhizoma Anemarrhenae total phenol extract, its preparation method and application |
| KR20080045770A (en) * | 2006-11-21 | 2008-05-26 | 김우원 | Process of manufacturing korean bread contining korean medicine |
| CN101229316A (en) * | 2008-01-31 | 2008-07-30 | 广东药学院 | Rhizoma anemarrhenae extrac and applications as type 2 diabetes-curing medicine thereof |
| JP2011157344A (en) * | 2009-10-23 | 2011-08-18 | Kracie Seiyaku Kk | Aroma composition having action for improving psychosomatic disorder and for upgrading action efficiency of brain, and preparation including the same |
| CN103830520A (en) * | 2012-11-26 | 2014-06-04 | 青岛百草汇中草药研究所 | New application of total saponins of rhizoma anemarrhenae |
| CN103479856A (en) * | 2013-09-22 | 2014-01-01 | 山东省医药工业研究所 | Rhizoma anemarrhenae chemical component cluster extracts and preparation process thereof |
| CN105596684A (en) * | 2016-02-01 | 2016-05-25 | 北京宜生堂医药科技研究有限公司 | Rhizoma anemarrhenae extract and lily and rhizoma anemarrhenae extract |
| CN105663626A (en) * | 2016-03-04 | 2016-06-15 | 广东药学院 | Rhizoma anemarrhenae effective part as well as preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 张晶等: "《中药化学》", 30 April 2015, 中国农业大学出版社 * |
| 张雅明: "《柏氏肛肠病学》", 31 January 2016, 上海科学技术出版社 * |
| 黄芳等: "知母提取物的降血糖作用", 《中国生化药物杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115572318A (en) * | 2022-10-23 | 2023-01-06 | 爱生泽(上海)生物科技有限公司 | Preparation method of anemarrhena oligosaccharide and application of anemarrhena oligosaccharide in cosmetics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013010383A1 (en) | Intestine-hydrating and laxative drink and preparation method therefor | |
| CN110559403B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| CN107753500A (en) | The Preparation method and use of oligosaccharide compositions in the wind-weed | |
| KR101228920B1 (en) | A composition comprising of a leaf extract of dendropanax morbifera for treating and preventing intestinal function disorder | |
| CN109662967A (en) | A kind of antidepressant and application thereof | |
| CN105963359A (en) | Application of all-cannabinoid in preparation of drugs for treating depression | |
| CN103191175B (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN101199806A (en) | Drug for treating laxness, preparing method and quality controlling method thereof | |
| CN101396435B (en) | Traditional Chinese medicine for treating gastrosis and preparation method and use thereof | |
| CN104095912B (en) | Treat the preparation method of the Chinese patent drug of rheumatism bone disease | |
| CN107595870B (en) | Brain-strengthening and nerve-soothing pharmaceutical composition, pharmaceutical preparation, application and preparation method | |
| CN1579485B (en) | Traditional Chinese medicinal composition for treating intestinal function disorder and its preparation method | |
| CN107260851B (en) | Traditional Chinese medicine composition for treating deficiency constipation | |
| CN103463204A (en) | Medicine for treating constipation and preparation method thereof | |
| CN107126463A (en) | A kind of anti-diarrhea Chinese medical extract and its application | |
| CN109481515A (en) | A kind of solid dispersions effervescent tablet promoting digestive function | |
| CN103751239B (en) | A kind of preparation method and applications of Radix Et Caulis Acanthopanacis Senticosi total glucosides and manyprickle acanthopanax general glycosides formulation | |
| CN103316103A (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN100396294C (en) | Application of resina ferulae in preparation of medicament for treating irritable bowel syndrome(IBS) | |
| CN102688254B (en) | Medicinal composition for treating chronic diarrhea and preparation method and use thereof | |
| CN1284564C (en) | Oral Chinese traditional medicine preparation for treating constipation | |
| US20220193171A1 (en) | Pharmaceutical composition comprising mixture extract of coptis rhizome and schizonepeta tenuifolia as active ingredient for prevention or treatment of inflammatory bowel disease | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN100522158C (en) | Application of Gulunbin, iso-gulunbin and fibleucin for preparing medicine for treating arthritis | |
| CN105617340A (en) | Traditional Chinese medicine for treating chronic gastritis and gastric ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180306 |
|
| WD01 | Invention patent application deemed withdrawn after publication |